Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (3) , 1834-1848
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War (W81XWH-19-1-0622)
- Santé (270746)
This publication has 31 references indexed in Scilit:
- GLP-1 receptor agonists: a review of head-to-head clinical studiesTherapeutic Advances in Endocrinology and Metabolism, 2014
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyThe Lancet Neurology, 2014
- Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse ModelDiabetes, 2014
- The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?Current Opinion in Pharmacology, 2013
- Site-Specific PEGylated Exendin-4 Modified with a High Molecular Weight Trimeric PEG Reduces Steric Hindrance and Increases Type 2 Antidiabetic Therapeutic EffectsBioconjugate Chemistry, 2012
- Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersBritish Journal of Pharmacology, 2012
- The structure and function of the glucagon‐like peptide‐1 receptor and its ligandsBritish Journal of Pharmacology, 2012
- Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in RodentsHormone and Metabolic Research, 2011
- Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for NeurodegenerationNeurotherapeutics, 2011
- Experimental Autoimmune Encephalomyelitis in the MouseCurrent Protocols in Immunology, 2010